» Articles » PMID: 12545162

Transient Activation of NF-kappaB Through a TAK1/IKK Kinase Pathway by TGF-beta1 Inhibits AP-1/SMAD Signaling and Apoptosis: Implications in Liver Tumor Formation

Overview
Journal Oncogene
Date 2003 Jan 25
PMID 12545162
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

NF-kappaB has been implicated in the regulation of apoptosis, a key mechanism of normal and malignant growth control. Previously, we demonstrated that inhibition of NF-kappaB activity by TGF-beta1 leads directly to induction of apoptosis of murine B-cell lymphomas and hepatocytes. Thus, we were surprised to determine that NF-kappaB is transiently activated in response to TGF-beta1 treatment. Here we elucidate the mechanism of TGF-beta1-mediated regulation of NF-kappaB and induction of apoptosis in epithelial cells. We report that TGF-beta1 activates IKK kinase, which mediates IkappaB-alpha phosphorylation. In turn, the activation of IKK following TGF-beta1 treatment is mediated by the TAK1 kinase. As a result of NF-kappaB activation, IkappaB-alpha mRNA and protein levels are increased leading to postrepression of NF-kappaB and induction of cell death. Inhibition of NF-kappaB following TGF-beta1 treatment increased AP-1 complex transcriptional activity through sustained c-Jun phosphorylation, thereby potentiating AP-1/SMADs-mediated cell killing. Furthermore, TGF-beta1-mediated upregulation of Smad7 appeared independent of NF-kappaB. In hepatocellular carcinomas of TGF-beta1 or TGF-alpha/c-myc transgenic mice, we observed constitutive activation of NF-kappaB that led to inhibition of JNK signaling. Overall, our data illustrate an autocrine mechanism based on the ability of IKK/NF-kappaB/IkappaB-alpha signaling to negatively regulate NF-kappaB levels thereby permitting TGF-beta1-induced apoptosis through AP-1 activity.

Citing Articles

Exploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies.

Sheikh K, Amjad M, Irfan M, Anjum S, Majeed T, Riaz M Onco Targets Ther. 2025; 18:233-262.

PMID: 39989503 PMC: 11846535. DOI: 10.2147/OTT.S493643.


Endothelial-to-mesenchymal transition in the tumor microenvironment: Roles of transforming growth factor-β and matrix metalloproteins.

Du F, Li J, Zhong X, Zhang Z, Zhao Y Heliyon. 2024; 10(21):e40118.

PMID: 39568849 PMC: 11577214. DOI: 10.1016/j.heliyon.2024.e40118.


Eye on the horizon: The metabolic landscape of the RPE in aging and disease.

Hansman D, Du J, Casson R, Peet D Prog Retin Eye Res. 2024; 104:101306.

PMID: 39433211 PMC: 11833275. DOI: 10.1016/j.preteyeres.2024.101306.


The Expression of Serglycin Is Required for Active Transforming Growth Factor β Receptor I Tumorigenic Signaling in Glioblastoma Cells and Paracrine Activation of Stromal Fibroblasts via CXCR-2.

Manou D, Golfinopoulou M, Alharbi S, AlGhamdi H, Alzahrani F, Theocharis A Biomolecules. 2024; 14(4).

PMID: 38672477 PMC: 11048235. DOI: 10.3390/biom14040461.


TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.